



Inovio Pharmaceuticals, Inc. Class Action Lawsuit - INO

Inovio Pharmaceuticals, Inc.
NASDAQ: INO

Affected INO Investor Summary

- **Who:** Inovio Pharmaceuticals, Inc. ([NASDAQ: INO](#))
- **What:** Securities fraud class action lawsuit filed
- **Class Period:** October 10, 2023 through December 26, 2025
- **Deadline to Seek Lead Plaintiff Status:** April 7, 2026
- **Key Lawsuit Allegations:** Material misstatements and/or omissions concerning the company's ability to meet customer demand for its service
- **Investor Action:** Contact [Kessler Topaz Meltzer & Check, LLP \(www.ktmc.com\)](#) for recovery options

The *Inovio Pharmaceuticals, Inc.* class action lawsuit was filed on behalf of those who purchased or otherwise acquired *Inovio Pharmaceuticals, Inc.* ("*Inovio*") (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025, inclusive (the "Class Period"). Captioned *Carlson v. Inovio Pharmaceuticals, Inc.*, No. 26-cv-00803 (E.D. Pa.) the *Inovio* class action lawsuit alleges that *Inovio* and/or certain of its officers and/or directors violated federal securities laws by making false or misleading statements and/or omitted to disclose material information.

If you lost money as a result of your *Inovio* investment and want to find out more about this action and your rights, fill out the form on this page or contact attorney Jonathan Naji, Esq. of KTMC by calling (484) 270-1453 or via e-mail at info@ktmc.com. Lead plaintiff motions must be filed with the court no later than April 7, 2026.

COMPLAINT ALLEGATION SUMMARY:

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company's business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) manufacturing for *Inovio's* proprietary investigational medical device, CELLECTRA, was deficient; (2) accordingly, *Inovio* was unlikely to submit the Biologics License Application ("BLA") for INO-3107, *Inovio's* lead product candidate for the treatment of recurrent respiratory papillomatosis, by the second half of 2024; (3) there was insufficient information to justify INO-3107 BLA's eligibility for accelerated approval and/or priority review by the FDA; and (4) as a result of the foregoing, Defendants' statements about the company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

WHY DID INOVIO'S STOCK DROP?

On August 8, 2024, *Inovio* issued a press release reporting its second quarter financial results, and announced that it expected to submit the BLA for INO-3107 in mid-2025,

which was a full year later than its initially projected submission timeline. On this news, *Inovio's* stock price fell \$0.27 per share, or 3.1%. Then, on December 29, 2025, *Inovio* announced that the FDA had accepted the INO-3107 BLA on a standard timeline, rather than the accelerated timeline. *Inovio* admitted that the FDA indicated that the company did not submit adequate information needed to justify its eligibility for the accelerated review timeline. Upon this announcement, *Inovio's* stock price fell \$0.56 per share, or 24.45%.

THE LEAD PLAINTIFF PROCESS:

The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired *Inovio* securities during the Class Period to seek appointment as lead plaintiff in the *Inovio* class action lawsuit. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Filling out the online form above or communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:

Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over \$25 billion for our clients and the classes they represent.

